Skip to content

Effect of k receptor analgesic drug on gastrointestinal function in critical patients following abdominal surgery

Effect of k receptor analgesic drug on gastrointestinal function in critical patients following abdominal surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049774
Enrollment
Unknown
Registered
2021-08-09
Start date
2021-08-18
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abdominal surgery

Interventions

k receptor analgesic drug group:Use k receptor analgesic drug for analgesia
µ receptor analgesic drug group:Use µ receptor analgesic drug for analgesia

Sponsors

the Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with abdominal surgery who need postoperative analgesia and ICU monitoring; 2. Aged 18 to 80 years; 3. The estimated treatment time in the ICU is greater than 7 days; 4. Voluntarily sign the informed consent and participate in the research.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to opioids; 2. Patients with gastrointestinal ischemia and other diseases; 3. Mental patients; 4. Long-term use of opioids for more than 2 weeks (oral or intravenous, pain reliever), drug addiction; 5. Liver and kidney insufficiency (liver enzymes are more than 3 times the normal value or child score is more than grade B; creatinine clearance rate <50ml/min); 6. Patients with bradycardia (heart rate <= 50 beats/min), third-degree atrioventricular block, systolic blood pressure <= 90 mmHg; 7. Pregnant or lactating women; 8. Patients with persistent epilepsy; 9. Patients with severe gastrointestinal dysfunction; 10. Patients who are expected to die within 48 hours; 11. Those who participated in other clinical trials within 30 days before enrollment; 12. Those who are deemed inappropriate by the investigator to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
Gastrointestinal function;analgesic effect;Mechanical ventilation time;Duration of ICU stay;

Countries

China

Contacts

Public ContactLiu Xuefang

the Second Hospital of Hebei Medical University

liuxuefang2015@hb2h.com+86 15931686132

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026